Reneo Pharmaceuticals, Inc.
Reneo Pharmaceuticals, Inc. is listed today as OnKure Therapeutics, Inc.: market value, financials and filings are on its company page.
Funding rounds
3 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Oct 2024 | $65 M | Private placement after listing | $50 to $250 million | equity | SEC | |
| Dec 2020 | $47 M | No. 3 | $10 to $50 million | equity | SEC | |
| May 2019 | $25 M | No. 2 | $10 to $50 million | equity | SEC | |
| Dec 2017 | $22 M | No. 1 | $10 to $50 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Reneo Pharmaceuticals, Inc. chose not to state its revenue in its newest notice of a funding round (Oct 2024).
SEC Form D · Oct 2024
The industry group it chose in its notices: Pharmaceuticals.
SEC Form D · Oct 2024
That is all the official record says: Reneo Pharmaceuticals, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services of Reneo Pharmaceuticals, Inc. are on record.
Investors#
7 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Nea 15 GP, LLC | Other | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| NEA Partners 15, L.P. | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| New Enterprise Associates 15, L.P. | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Novo Holdings A/s | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| RiverVest Venture Fund III, L.P. | Venture capital | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| RiverVest Venture Fund III (Ohio), L.P. | Venture capital | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| RiverVest Venture Fund IV, L.P. | Venture capital | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 16 investors.
Largest shareholders today
Institutions holding OnKure Therapeutics, Inc. shares, as of Sep 30, 2026.
- BVF Inc/il$11 M9.99%
- Ra Capital Management, L.P.$11 M9.87%
- Acorn Capital Advisors, LLC$8 M7.01%
- StepStone Group LP$7 M6.57%
- ADAR1 Capital Management, LLC$6 M5.53%
- Vivo Capital, LLC$5 M4.76%
- BlackRock, Inc.$5 M4.14%
- Vanguard Capital Management LLC$4 M3.67%
- Prosight Management, LP$4 M3.27%
- Adage Capital Partners GP, L.L.C.$3 M2.97%
- Vestal Point Capital, LP$3 M2.69%
- Sio Capital Management, LLC$3 M2.67%
- Bank Of America Corp /de/$3 M2.47%
- Logos Global Management LP$3 M2.38%
- Geode Capital Management, LLC$2 M1.78%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Dylan Hartley | Executive officer | Oct 2024 |
| Jason Leverone | Executive officer | Oct 2024 |
| Nicholas Saccomano | Executive officer | Oct 2024 |
| Samuel Agresta | Executive officer | Oct 2024 |
| Alejandro Dorenbaum, M.D. | Executive officer | Dec 2020 |
| Gregory Flesher | Executive officer | Dec 2020 |
| Mike Cruse | Executive officer | Dec 2020 |
| Wendy Johnson | Executive officer | Dec 2020 |
| Niall O'Donnell, Ph.D. | Executive officer | May 2019 |
| Michael Grey | Executive officer | Jan 2018 |
| Niall O'Donnell | Executive officer | Jan 2018 |
| Andrew Johm Phillips | Director | Oct 2024 |
| Edward T. Mathers | Director | Oct 2024 |
| Isaac M. Manke | Director | Oct 2024 |
| Michael G. Grey | Director | Oct 2024 |
| Nicholas Saccomano | Director | Oct 2024 |
| R. Michael Carruthers | Director | Oct 2024 |
| Valerie M. Jansen | Director | Oct 2024 |
| Bali Muralidhar | Director | Dec 2020 |
| Ed Mathers | Director | Dec 2020 |
| Gregory Flesher | Director | Dec 2020 |
| Johan Kordel, Ph.D. | Director | Dec 2020 |
| Kenneth Harrison | Director | Dec 2020 |
| Lon Cardon, Ph.D. | Director | Dec 2020 |
| Michael Grey | Director | Dec 2020 |
| Niall O'Donnell, Ph.D. | Director | Dec 2020 |
| Stacey Seltzer | Director | Dec 2020 |
| Art Pappas | Director | May 2019 |
| Niall O'Donnell | Director | Jan 2018 |
| Scott Weiner | Director | Jan 2018 |
Went public since 2021. Its SEC number is that of a company listed on a stock exchange.